Tecovirimat 200 mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 200 mg

Reference Brands: TPOXX (USA), Tecovirimat SIGA (EU),

Category: Anti Viral

Tecovirimat (also known as TPOXX or ST-246) is FDA-approved for the treatment of human smallpox disease caused by Variola virus in adults and children.

Product Description:

Tecovirimat, marketed under the brand name TPOXX, is an antiviral medication with specific activity against orthopoxviruses, including smallpox and mpox. It made medical history in 2018 as the first antipoxviral drug approved in the United States, representing a major advancement in the treatment and preparedness for orthopoxvirus infections. Tecovirimat is designed to prevent the spread of virus within the body rather than directly killing the virus.

The drug works by inhibiting a viral protein involved in cellular transmission, effectively blocking the virus’s ability to exit infected cells and spread to healthy cells. This mechanism helps limit disease progression and supports the immune system in controlling the infection. Tecovirimat has demonstrated strong effectiveness in laboratory and animal studies, providing protection against infections such as mpox and rabbitpox.

Clinical experience has shown that tecovirimat is generally well tolerated in humans, with no serious side effects reported in studies. It was first used for human treatment in December 2018 following a laboratory-acquired vaccinia virus infection. Tecovirimat remains a critical therapeutic option for managing orthopoxvirus infections and enhancing global public health preparedness.